Aberdare Ventures was founded in 1999 by partner Paul Klingenstein. Based in San Francisco, California, Aberdare Ventures has over $400 million of capital committed to the healthcare technology industry with emphases on medical device and biopharmaceutical product companies.

AEB, founded in 1999, produces compact electron beam emitters replace thermal and chemical processes for cleaner, more efficient, lower-cost manufacturing. Today, more than 40 customers worldwide rely on AEB Emitters to address a range of applications across sterilization, pollution abatement, curing and polymer treatment sectors.

American Tower, the leading independent owner, operator and developer of broadcast and wireless communication sites in North America, was founded in 1995. American Tower operates approximately 15,000 sites in the United States, Mexico and Brazil, including approximately 300 broadcast tower sites.

Apax Partners is an independent global private equity advisory firm with offices located in nine countries spanning three continents. Funds advised by Apax Partners (Apax Funds) commit capital on behalf of a diverse range of investors, which include public and private pension funds, insurance companies, university endowments and other financial institutions. Apax Funds invest in five key growth sectors: Tech & Telecom, Retail & Consumer, Media, Healthcare and Financial & Business Services.

Azimuth Systems, founded in 2002, is a leading provider of wireless data communications test solutions for 4G technologies like WiMAX, LTE, UMB and Wi-Fi. Azimuth's products are used by the world's top wireless semiconductor, system vendors and service providers to speed time-to-market and improve wireless product quality.

BiPar Sciences, Inc. is a biopharmaceutical company focused on the development of novel oncological therapeutics. The Since its founding in 2002, BiPar Sciences Inc. has raised over $53 million in funding with major investors including: Domain Associates, Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Company, Quantum Technology Partners, and Lighthouse Capital Partners. With lead candidate BSI-201, BiPar Sciences Inc. aims its therapeutics at inducing death of select tumor cells in multiple cancers.

Established in 1992, the Clinical Trials Office is the main administrative arm of clinical research for the Columbia University Medical Center at New York Presbyterian Hospital. Since its inception, the CTO has negotiated over 1,600 contracts representing over 500 sponsors.

Demandware, founded in 2004, provides a fully-customizable, on-demand e-commerce platform for online retailers. Based on their Active Merchandising platform and architecture, Demandware has attracted world-class clients like Jones New York, Barneys New York, Nine West, Timberland and Bare Escentuals.

Fidelity Investments is an international provider of financial services and investment resources that help individuals and institutions meet their financial objectives. In addition to more than 300 Fidelity mutual funds, the company also offer discount brokerage services, retirement services, estate planning, wealth management, securities execution and clearance, and life insurance.

Fidelity offers investment management, retirement planning, brokerage, and human resources and benefits outsourcing services to 24 million individuals and institutions as well as through 5,500 financial intermediary firms. The firm is the largest mutual fund company in the United States, the No. 1 provider of workplace retirement savings plans, the largest mutual fund supermarket and a leading online brokerage firm.

The Ford School of Public Policy is known to offer outstanding education for leadership in public policy analysis and public management and to excel in social science research that illuminates public policy issues and promotes better public policy. The program was founded in 1914 as the Institute of Public Administration and renamed the Ford School in 1999. Undergraduate, master’s and doctoral studies programs are all offered.

GlycosBio, formed in 2007, develops a variety of high value chemicals using glycerin and other feedstocks, including oils and free fatty acids. The company produces these products using its novel platform technology, significantly reducing the production cost of these chemicals compared to petrochemical-based manufacturing while using an environmentally friendly process.

Founded in 1996, the International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership that aims to prevent HIV infection through the research and development of HIV vaccine candidates. In addition to its scientific research and development efforts, IAVI conducts HIV/AIDS policy analyses and acts as an international advocate for the advancement of HIV prevention through vaccine development.

Konarka, founded in 2001, is developing and advancing nano-enabled polymer photovoltaic materials that are lightweight, flexible and more versatile than traditional solar materials. Using proprietary materials, Konarka scientists and engineers created an entirely unique solar material, Power Plastic, a new breed of coatable, flexible, plastic photovoltaics can be used in a wide range of applications.

MicroCHIPS, Inc., based in Bedford, Massachusetts, is a biotechnology company that develops implantable drug delivery and biochemical sensing systems. MicroCHIPS was founded in 1999 by Dr. John Santini, Professors Michael Cima and Robert Langer of the Massachusetts Institute of Technology, and Terry McGuire of Polaris Venture Partners. The company has since attracted over $56 million in capital from leading venture and corporate investors with its promising implantable glucose-sensing platform.

The mission of the Massachusetts Institute of Technology Media Lab is to foster the invention of new technologies and concepts for Human Augmentation, with an emphasis on learning and cognition, arts and expression, affect and health, and social and economic development. The Media Lab serves as a unique bridge between inventors, academics, and the larger society, providing opportunities for theoretical prototypes to have a profound and pragmatic influence on society.

Pyramis Global Advisors is an investment management firm focused on serving institutional investors including corporate and public retirement funds, endowments, foundations, and other institutions, as well as non-U.S. investors. Pyramis offers active and risk-controlled domestic equity, international equity, fixed-income, high yield, real estate, and alternative strategies including equity market neutral and 130/30 disciplines.

The Scottsdale Cultural Council is the non-profit organization that shapes and enhances the arts and cultural affairs of the City of Scottsdale. The Council manages the Scottsdale Center for the Performing Arts, the Scottsdale Museum of Contemporary Art, and the Scottsdale Public Art Program under a master agreement with the City.

Venrock is a premier venture capital firm with offices in Palo Alto, New York, Cambridge, MA, and Israel. Originally established as the venture capital arm of the Rockefeller family, Venrock continues a seven-decade tradition of partnering with entrepreneurs to establish successful, enduring companies. Having invested $2.2 billion in 417 companies resulting in 124 IPOs and 117 M&A exits over the past 39 years, Venrock's investment returns place it among the top tier venture capital firms that have achieved consistently superior performance. With a primary focus on technology, healthcare, and energy, portfolio companies have included Apple Computer, Centocor, Check Point Software, DoubleClick, Gilead Sciences, Idec Pharmaceuticals, Illumina, Intel, Millennium Pharmaceuticals, Sirna Therapeutics, and StrataCom.

ZymoGenetics was founded in 1981 by three professors: Earl Davie and Benjamin Hall from the University of Washington and the late Michael Smith, 1993 Nobel Laureate in Chemistry and Professor of Biochemistry at the University of British Columbia. In 2000, Bruce Carter, ZymoGenetics’ President and Chief Executive Officer, raised $150 million in private placement financing and reestablished it as an independent biotechnology company. Later that year, ZymoGenetics completed an initial public offering and began trading on the Nasdaq stock exchange. ZymoGenetics has recently shifted its focus on therapeutic protein drug development to the discovery of antibodies and antibody therapeutics.